Abstracts tagged "hyperuricemia"

Abstract Number: 1913 • 2012 ACR/ARHP Annual Meeting
Complete Tophus Response in Patients with Chronic Gout Initiating Pegloticase Treatment
Michael A. Becker¹, Neil J. Gonter², Janet E. Pope³, Raymond L. Malamet⁴ and Herbert S. B. Baraf⁵, ¹Medicine, University of Chicago, Chicago, IL, ²Rheumatology Associates of North Jersey, Teaneck, NJ, ³Medicine/Rheumatology, St. Joseph Health Care London, University of Western Ontario, London, ON, Canada, ⁴Global Medical Affairs, Savient Pharmaceuticals, Inc., Bridgewater, NJ, ⁵Arthritis & Rheumatism Associates, Wheaton, MD
Background/Purpose: Pegloticase, a recombinant modified mammalian uricase that acts via enzymatic degradation of uric acid to allantoin, is approved in the US for the treatment…
Abstract Number: 1916 • 2012 ACR/ARHP Annual Meeting
Serum Uric Acid As a Biomarker for Mitigation of Infusion Reactions in Patients Treated with Pegloticase for Refractory Chronic Gout
Herbert S. B. Baraf¹, Robert A. Yood², John S. Sundy³, Faith D. Ottery⁴ and Michael A. Becker⁵, ¹Arthritis & Rheumatism Associates, Wheaton, MD, ²Reliant Medical Group, Worcester, MA, ³Duke Clinical Research Institute, Duke University Medical Center, Durham, NC, ⁴Medical Affairs, Savient Pharmaceuticals, Inc., East Brunswick, NJ, ⁵Medicine, University of Chicago, Chicago, IL
Background/Purpose: Using data pooled from the randomized, placebo-controlled trials (RCTs) of pegloticase, post-hoc analyses of urate-lowering, antibody titers and the patterns of infusion-related reactions (IRs)…
Abstract Number: 170 • 2012 ACR/ARHP Annual Meeting
Relative Risk of Infusion Reactions with KRYSTEXXA® (pegloticase) From Post-Approval Safety Data: Results From Sept 2010 to June 2012
Raymond L. Malamet¹, Tina L. Howson², Anthony E. Yeo³, Kenneth M. Bahrt⁴ and Marsha Wolfson³, ¹Global Medical Affairs, Savient Pharmaceuticals, Inc., Bridgewater, NJ, ²Savient Pharmaceuticals, Inc., Bridgewater, NJ, ³Savient Pharmaceuticals, Inc., East Brunswick, NJ, ⁴Medical Affairs, Savient Pharmaceuticals, Inc., Bridgewater, NJ
Background/Purpose: During randomized clinical trials (RCTs) with pegloticase, the incidence of infusion-related reactions (IRs) was 26% including 5 cases of anaphylaxis (determined post-hoc using published…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

ACR Abstract Embargo Policy

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. Academic institutions, private organizations and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part a scientific presentation or presentation of additional new information that will be available at the time of the meeting) is under embargo until Saturday, November 11, 2023.

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying financial and other sponsors about this policy. If you have questions about the abstract embargo policy, please contact the public relations department at [email protected].

Copyright Policy

View ACR Policies.